New Double-Stranded Twist on NGS Adds More Depth to Each Run

Emphasizing the value of uniform target capture, Twist Biosciences describes how using dsDNA probes can increase confidence in sequencing reads while reducing costs.

RenMab™ Mouse Set to Become the Leading Platform for Generating Human...

With large scale animal breeding capacity, antibody discovery, and preclinical pharmacology services, Biocytogen provides seamless integrated antibody discovery services to the biomedical community for a true one-stop solution from target to IND application.

Tapping of Cell Signaling Reveals Orphan Receptors’ Connections

The cell signaling network that encompasses GPCRs and their peptide ligands has been expanded by about 17% with the discovery of five new signaling systems. Historically, the discovery of GPCR-ligand signaling systems has often translated into clinical opportunities. The newfound GPCR-ligand signaling systems, then, may stimulate research into their physiological roles and therapeutic potential.

The Therapeutic Antibody Screening Revolution in the Post Genomics Era

In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.

Jumping Genes Found in ALS Suggest Possible Therapeutic Directions

Researchers at Cold Spring Harbor Laboratory identified three different molecular subtypes of amyotrophic lateral sclerosis. One group, comprising 20% of samples, was characterized by retrotransposon reactivation and dysfunction of a gene that silences jumping genes.

Ordinary Bugs Can Revert to Superbugs, Defeating Routine Clinical Screens

Disease-causing bacteria carry antibiotic resistance genes that are dormant as a result of a genetic mutation. During screening, the bacteria appears susceptible to antibiotics. However, such mutations easily become lost, rapidly transforming the bacteria into drug-resistant strains, dramatically increasing the risk that the drug therapy will fail.

MorphoSys, Galapagos Halt Development of Atopic Dermatitis Candidate Licensed to Novartis

MorphoSys and Galapagos are halting development of MOR106—an atopic dermatitis candidate the companies licensed to Novartis last year for potentially more than $1 billion—after an interim futility analysis of a Phase II trial showed the drug was unlikely to meet the study’s primary endpoint.

Biomarkers Linked to Specific Behaviors in Depression Identified for Precision Medicine

Studies by UC Berkeley-led researchers identified neural subcircuits and genetic biomarkers in the brain that were linked specifically with a lack of motivation in a mouse model of depression. The team suggests that understanding brain alterations linked with certain types of symptoms may lead to new approaches to reversing these specific symptoms.

Peripheral Vision: Cygnal Looks Beyond the CNS to Develop Drugs

Cygnal Therapeutics, a spinout of Flagship Pioneering, has emerged from stealth mode to develop drugs based on pathways and targets the company has discovered in the peripheral nervous system, with an initial focus on cancer and inflammatory disease.

Targeting the Inner Ear

There are many types and causes of sensorineural hearing loss. You can lose hearing from exposure to loud noises, medications with toxic side effects, or simply having been born with congenital hearing loss. Aging is a major risk factor too. The disorders are varied, but the treatments are not. There are at present no FDA approved treatments for sensorineural hearing loss, save hearing aids and cochlear implants.

Recently Featured

Stay Connected

Scroll Up